| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 33.33% | Goldman Sachs | $32 → $28 | Maintains | Neutral |
| 08/07/2023 | 52.38% | JP Morgan | $33 → $32 | Maintains | Neutral |
| 06/27/2023 | 100% | RBC Capital | $40 → $42 | Maintains | Outperform |
| 02/03/2023 | 95.24% | Piper Sandler | → $41 | Initiates Coverage On | → Overweight |
| 12/01/2022 | 57.14% | JP Morgan | $48 → $33 | Maintains | Neutral |
| 11/17/2022 | 52.38% | Goldman Sachs | $17 → $32 | Upgrades | Sell → Neutral |
| 08/05/2022 | 76.19% | SVB Leerink | $33 → $37 | Maintains | Outperform |
| 07/27/2022 | 57.14% | SVB Leerink | → $33 | Upgrades | Market Perform → Outperform |
| 05/24/2022 | -23.81% | Goldman Sachs | $20 → $16 | Maintains | Sell |
| 05/17/2022 | 57.14% | SVB Leerink | $30 → $33 | Maintains | Market Perform |
| 03/07/2022 | 9.52% | Goldman Sachs | $37 → $23 | Maintains | Sell |
| 03/03/2022 | 357.14% | HC Wainwright & Co. | $98 → $96 | Maintains | Buy |
| 02/25/2022 | 219.05% | RBC Capital | $61 → $67 | Maintains | Outperform |
| 02/24/2022 | 357.14% | HC Wainwright & Co. | $98 → $96 | Maintains | Buy |
| 02/22/2022 | 42.86% | SVB Leerink | $32 → $30 | Maintains | Market Perform |
| 02/18/2022 | 366.67% | HC Wainwright & Co. | $95 → $98 | Maintains | Buy |
| 02/16/2022 | 109.52% | Canaccord Genuity | $52 → $44 | Maintains | Buy |
| 12/03/2021 | 157.14% | B of A Securities | → $54 | Initiates Coverage On | → Buy |
| 11/18/2021 | 100% | SVB Leerink | $50 → $42 | Maintains | Market Perform |
| 11/04/2021 | 352.38% | HC Wainwright & Co. | $93 → $95 | Maintains | Buy |
| 07/30/2021 | 342.86% | HC Wainwright & Co. | $88 → $93 | Maintains | Buy |
| 07/30/2021 | 85.71% | Goldman Sachs | $58 → $39 | Downgrades | Neutral → Sell |
| 07/01/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 06/10/2021 | 319.05% | HC Wainwright & Co. | → $88 | Initiates Coverage On | → Buy |
| 04/30/2021 | 209.52% | Canaccord Genuity | $57 → $65 | Maintains | Buy |
| 03/01/2021 | 157.14% | JP Morgan | → $54 | Downgrades | Overweight → Neutral |
| 02/26/2021 | 138.1% | SVB Leerink | $55 → $50 | Downgrades | Outperform → Market Perform |
| 01/27/2021 | 161.9% | SVB Leerink | $51 → $55 | Maintains | Outperform |
| 12/28/2020 | 171.43% | Canaccord Genuity | $70 → $57 | Maintains | Buy |
| 12/09/2020 | 190.48% | SVB Leerink | $67 → $61 | Maintains | Outperform |
| 10/22/2020 | 119.05% | Barclays | → $46 | Upgrades | Equal-Weight → Overweight |
| 10/19/2020 | 228.57% | Needham | $71 → $69 | Maintains | Buy |
| 10/19/2020 | 233.33% | Canaccord Genuity | $72 → $70 | Maintains | Buy |
| 10/19/2020 | 219.05% | SVB Leerink | $72 → $67 | Maintains | Outperform |
| 10/19/2020 | 247.62% | Piper Sandler | $80 → $73 | Maintains | Overweight |
| 07/31/2020 | 242.86% | Cantor Fitzgerald | $70 → $72 | Maintains | Overweight |
| 06/15/2020 | 242.86% | SVB Leerink | $70 → $72 | Maintains | Outperform |
| 06/15/2020 | 257.14% | Citigroup | $64 → $75 | Maintains | Buy |
| 05/04/2020 | 290.48% | JP Morgan | $72 → $82 | Maintains | Overweight |
| 03/04/2020 | 138.1% | Barclays | → $50 | Initiates Coverage On | → Equal-Weight |
| 02/14/2020 | 233.33% | Cantor Fitzgerald | $64 → $70 | Reiterates | → Overweight |
| 12/09/2019 | 133.33% | BMO Capital | $45 → $49 | Maintains | Outperform |
| 12/04/2019 | 223.81% | JP Morgan | $80 → $68 | Maintains | Overweight |
| 11/26/2019 | 204.76% | Cantor Fitzgerald | → $64 | Initiates Coverage On | → Overweight |
| 11/05/2019 | 204.76% | Citigroup | $80 → $64 | Maintains | Buy |
| 09/23/2019 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 09/12/2019 | 114.29% | BMO Capital | → $45 | Initiates Coverage On | → Outperform |
| 05/23/2019 | 161.9% | Goldman Sachs | → $55 | Assumes | → Neutral |
| 02/20/2019 | — | Oppenheimer | Assumes | → Perform | |
| 02/15/2019 | 280.95% | Leerink Swann | → $80 | Upgrades | Market Perform → Outperform |
What is the target price for Agios Pharmaceuticals (AGIO)?
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by Goldman Sachs on November 3, 2023. The analyst firm set a price target for $28.00 expecting AGIO to rise to within 12 months (a possible 33.33% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Agios Pharmaceuticals (AGIO)?
The latest analyst rating for Agios Pharmaceuticals (NASDAQ: AGIO) was provided by Goldman Sachs, and Agios Pharmaceuticals maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Agios Pharmaceuticals (AGIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agios Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agios Pharmaceuticals was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Agios Pharmaceuticals (AGIO) correct?
While ratings are subjective and will change, the latest Agios Pharmaceuticals (AGIO) rating was a maintained with a price target of $32.00 to $28.00. The current price Agios Pharmaceuticals (AGIO) is trading at is $21.00, which is out of the analyst's predicted range.